A detailed history of Ballentine Partners, LLC transactions in Incyte Corp stock. As of the latest transaction made, Ballentine Partners, LLC holds 5,335 shares of INCY stock, worth $386,307. This represents 0.01% of its overall portfolio holdings.

Number of Shares
5,335
Previous 4,669 14.26%
Holding current value
$386,307
Previous $308,000 19.48%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 16, 2025

BUY
$65.08 - $83.38 $43,343 - $55,531
666 Added 14.26%
5,335 $368,000
Q3 2024

Oct 23, 2024

SELL
$57.33 - $68.61 $3,325 - $3,979
-58 Reduced 1.23%
4,669 $308,000
Q2 2024

Aug 06, 2024

BUY
$51.18 - $63.75 $9,314 - $11,602
182 Added 4.0%
4,727 $286,000
Q1 2024

Apr 11, 2024

BUY
$56.55 - $66.59 $4,693 - $5,526
83 Added 1.86%
4,545 $258,000
Q4 2023

Jan 23, 2024

BUY
$52.16 - $64.19 $232,737 - $286,415
4,462 New
4,462 $280,000
Q4 2022

Jan 27, 2023

BUY
$67.18 - $84.11 $175,272 - $219,442
2,609 New
2,609 $0

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.1B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Ballentine Partners, LLC Portfolio

Follow Ballentine Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ballentine Partners, LLC with notifications on news.